Literature DB >> 19224136

Enzymatic activity and thermal stability of PEG-alpha-chymotrypsin conjugates.

José A Rodríguez-Martínez1, Izarys Rivera-Rivera, Ricardo J Solá, Kai Griebenow.   

Abstract

Alpha-chymotrypsin was chemically modified with methoxypoly(ethylene glycol) (PEG) of different molecular weights (700, 2,000, and 5,000 Da) and the amount of polymer attached to the enzyme was varied systematically from 1 to 9 PEG molecules per enzyme molecule. Upon PEG conjugation, enzyme catalytic turnover (k (cat)) decreased by 50% and substrate affinity was lowered as evidenced by an increase in the K (M) from 0.05 to 0.19 mM. These effects were dependent on the amount of PEG bound to the enzyme but were independent of the PEG size. In contrast, stabilization toward thermal inactivation depended on the PEG molecular weight with conjugates with the larger PEGs being more stable.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224136      PMCID: PMC2719889          DOI: 10.1007/s10529-009-9947-y

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  18 in total

Review 1.  Proteases in organic synthesis.

Authors:  Frank Bordusa
Journal:  Chem Rev       Date:  2002-12       Impact factor: 60.622

Review 2.  Protein aggregation and its inhibition in biopharmaceutics.

Authors:  Wei Wang
Journal:  Int J Pharm       Date:  2005-01-06       Impact factor: 5.875

Review 3.  Protein drug stability: a formulation challenge.

Authors:  Sven Frokjaer; Daniel E Otzen
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

Review 4.  Stability of biocatalysts.

Authors:  Karen M Polizzi; Andreas S Bommarius; James M Broering; Javier F Chaparro-Riggers
Journal:  Curr Opin Chem Biol       Date:  2007-02-20       Impact factor: 8.822

5.  Site-specific PEGylation of hemoglobin at Cys-93(beta): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain.

Authors:  B N Manjula; A Tsai; R Upadhya; K Perumalsamy; P K Smith; A Malavalli; K Vandegriff; R M Winslow; M Intaglietta; M Prabhakaran; J M Friedman; A S Acharya
Journal:  Bioconjug Chem       Date:  2003 Mar-Apr       Impact factor: 4.774

6.  Chemical glycosylation: new insights on the interrelation between protein structural mobility, thermodynamic stability, and catalysis.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  FEBS Lett       Date:  2006-02-17       Impact factor: 4.124

7.  Effect of the covalent modification with poly(ethylene glycol) on alpha-chymotrypsin stability upon encapsulation in poly(lactic-co-glycolic) microspheres.

Authors:  Ingrid J Castellanos; Wasfi Al-Azzam; Kai Griebenow
Journal:  J Pharm Sci       Date:  2005-02       Impact factor: 3.534

8.  Structure of alpha-chymotrypsin refined at 1.68 A resolution.

Authors:  H Tsukada; D M Blow
Journal:  J Mol Biol       Date:  1985-08-20       Impact factor: 5.469

9.  Influence of modulated structural dynamics on the kinetics of alpha-chymotrypsin catalysis. Insights through chemical glycosylation, molecular dynamics and domain motion analysis.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  FEBS J       Date:  2006-10-31       Impact factor: 5.542

Review 10.  Biomedical and biotechnological applications of PEG- and PM-modified proteins.

Authors:  Y Inada; M Furukawa; H Sasaki; Y Kodera; M Hiroto; H Nishimura; A Matsushima
Journal:  Trends Biotechnol       Date:  1995-03       Impact factor: 19.536

View more
  21 in total

1.  Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity.

Authors:  Andrew J Keefe; Shaoyi Jiang
Journal:  Nat Chem       Date:  2011-12-11       Impact factor: 24.427

2.  Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo.

Authors:  Oliv Eidam; Chiara Romagnoli; Guillaume Dalmasso; Sarah Barelier; Emilia Caselli; Richard Bonnet; Brian K Shoichet; Fabio Prati
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-05       Impact factor: 11.205

3.  Modelling of electrokinetic phenomena for capture of PEGylated ribonuclease A in a microdevice with insulating structures.

Authors:  Marco A Mata-Gomez; Victor H Perez-Gonzalez; Roberto C Gallo-Villanueva; Jose Gonzalez-Valdez; Marco Rito-Palomares; Sergio O Martinez-Chapa
Journal:  Biomicrofluidics       Date:  2016-06-15       Impact factor: 2.800

Review 4.  How PEGylation influences protein conformational stability.

Authors:  Paul B Lawrence; Joshua L Price
Journal:  Curr Opin Chem Biol       Date:  2016-08-28       Impact factor: 8.822

5.  Simple Protein Modification Using Zwitterionic Polymer to Mitigate the Bioactivity Loss of Conjugated Insulin.

Authors:  Jinbing Xie; Yang Lu; Wei Wang; Hui Zhu; Zhigang Wang; Zhiqiang Cao
Journal:  Adv Healthc Mater       Date:  2017-03-24       Impact factor: 9.933

6.  Conformational and aggregation properties of a PEGylated alanine-rich polypeptide.

Authors:  Ayben Top; Christopher J Roberts; Kristi L Kiick
Journal:  Biomacromolecules       Date:  2011-05-09       Impact factor: 6.988

Review 7.  PEGylated Human Serum Albumin: Review of PEGylation, Purification and Characterization Methods.

Authors:  Parvin Akbarzadehlaleh; Mona Mirzaei; Mahdiyeh Mashahdi-Keshtiban; Karim Shamsasenjan; Hamidreza Heydari
Journal:  Adv Pharm Bull       Date:  2016-09-25

8.  Prevention of benzyl alcohol-induced aggregation of chymotrypsinogen by PEGylation.

Authors:  José A Rodríguez-Martínez; Izarys Rivera-Rivera; Kai Griebenow
Journal:  J Pharm Pharmacol       Date:  2011-05-03       Impact factor: 3.765

9.  PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity.

Authors:  Jun-Beom Park; Young Min Kwon; Tien-Yi Lee; Remy Brim; Mei-Chuan Ko; Roger K Sunahara; James H Woods; Victor C Yang
Journal:  J Control Release       Date:  2009-10-24       Impact factor: 9.776

Review 10.  Production and Purification of Therapeutic Enzymes.

Authors:  M Ângela Taipa; Pedro Fernandes; Carla C C R de Carvalho
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.